Tidal Investments LLC Purchases 6,558 Shares of Repligen Co. (NASDAQ:RGEN)

Tidal Investments LLC lifted its stake in shares of Repligen Co. (NASDAQ:RGEN) by 142.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,149 shares of the biotechnology company’s stock after purchasing an additional 6,558 shares during the quarter. Tidal Investments LLC’s holdings in Repligen were worth $1,659,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Toronto Dominion Bank grew its holdings in shares of Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale grew its holdings in shares of Repligen by 1.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after purchasing an additional 89 shares during the last quarter. MML Investors Services LLC grew its holdings in shares of Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares during the last quarter. Ballentine Partners LLC grew its holdings in shares of Repligen by 6.2% during the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 105 shares during the last quarter. Finally, CWM LLC grew its holdings in shares of Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 114 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

RGEN has been the topic of several recent research reports. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday. They set a “hold” rating and a $165.00 target price on the stock. Wells Fargo & Company initiated coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Finally, Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Repligen has an average rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Stock Down 1.7 %

Shares of NASDAQ RGEN opened at $158.14 on Wednesday. The company’s 50 day moving average price is $143.15 and its 200-day moving average price is $141.68. The company has a market capitalization of $8.86 billion, a P/E ratio of -427.41, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.23 EPS. Equities analysts forecast that Repligen Co. will post 1.54 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.